- Home
- BCYC vs HQL Comparison
BCYC vs HQL Comparison
Compare BCYC & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCYC | HQL |
|---|---|---|
| Founded | 2009 | 1992 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.7M | 490.5M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | BCYC | HQL |
|---|---|---|
| Price | $5.01 | $16.53 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $17.56 | N/A |
| AVG Volume (30 Days) | ★ 335.4K | 119.7K |
| Earning Date | 06-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.77 | $10.55 |
| 52 Week High | $9.94 | $17.80 |
Technical Indicators
Market Signals| Indicator | BCYC | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 38.55 | 48.12 |
| Support Level | N/A | $16.40 |
| Resistance Level | $5.90 | $17.51 |
| Average True Range (ATR) | 0.27 | 0.32 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 23.11 | 60.14 |
Price Performance
Historical ComparisonAbout BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.